An important goal of The National Institute on Drug Abuse (NIDA) is to foster the development of new approaches for drug addiction treatment and prevention. Our Center will advance this objective by providing an enabling resource for NIDA and NIH investigators for accelerating the progress of their addiction research, including but not limited to the discovery and characterization of novel small molecule compounds. The primary areas of focus of our program are the gene families represented by orphan and identified Seven Transmembrane G protein-coupled receptors (GPCRs) as well as nicotinic acetylcholine receptors. With NIDA support of our Duke P30 Center over, the past four years, we have established and maintained a cDNA collection containing the open reading frames for almost all human addiction associated GPCRs, and more importantly an expanding repository of off-the shelf cell-based assays for the GPCR targets of interest to NIDA funded scientists. Our efforts have produced collaborations with NIH/NIDA chemists and biologists at multiple other institutions, including multiple projects with the Molecular Libraries Probe Production Centers Network (MLPCN) that resulted in the discovery of novel probe compounds for the KOR, GPRs 33, 55, and the neurotensin 1 receptor. To continue our mission of providing a pharmacological treatment for drug addiction and maintaining our operation at current levels, we are seeking a renewal of funding as a NIDA P30 Center of Excellence that will enable our Center to remain at the forefront of drug addiction research. The primary scope of our work would include the identification and in cellulo and in vivo characterization of novel tool compounds using addiction models.
Our specific aims remain, to develop, maintain, and provide receptor cDNA and cell assay libraries, for immediate access by NID/VNIH investigators, to screen in a timely manner (days to weeks turnaround) the receptor targets provided by our collaborators against limited libraries (1000-5,000 compounds) provided by us or those scientists;and establish collaborative projects aimed towards the discovery and characterization of novel compounds targeting addictive behaviors including the new assays and technologies that will facilitate those discoveries. This strategy will expedite the identification of preclinical compounds as well as tool compounds to characterize the biology of addiction and provide an educational resource for collaborating scientists in drug discovery technology.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Center Core Grants (P30)
Project #
2P30DA029925-05
Application #
8742369
Study Section
Special Emphasis Panel (ZDA1)
Program Officer
Bough, Kristopher J
Project Start
2010-07-01
Project End
2019-04-30
Budget Start
2014-07-15
Budget End
2015-04-30
Support Year
5
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Duke University
Department
Anatomy/Cell Biology
Type
Schools of Medicine
DUNS #
City
Durham
State
NC
Country
United States
Zip Code
27705
Mackie, Duncan I; Al Mutairi, Fuad; Davis, Reema B et al. (2018) hCALCRL mutation causes autosomal recessive nonimmune hydrops fetalis with lymphatic dysplasia. J Exp Med 215:2339-2353
Toth, Krisztian; Slosky, Lauren M; Pack, Thomas F et al. (2018) Ghrelin receptor antagonism of hyperlocomotion in cocaine-sensitized mice requires ?arrestin-2. Synapse 72:
Fakhouri, Lara; Cook, Christopher D; Al-Huniti, Mohammed H et al. (2017) Design, synthesis and biological evaluation of GPR55 agonists. Bioorg Med Chem 25:4355-4367
Snyder, Joshua C; Rochelle, Lauren K; Ray, Caroline et al. (2017) Inhibiting clathrin-mediated endocytosis of the leucine-rich G protein-coupled receptor-5 diminishes cell fitness. J Biol Chem 292:7208-7222
Ray, Caroline; Soderblom, Erik J; Bai, Yushi et al. (2017) Probing the Allosteric Role of the ?5 Subunit of ?3?4?5 Nicotinic Acetylcholine Receptors by Functionally Selective Modulators and Ligands. ACS Chem Biol 12:702-714
Le Gonidec, Sophie; Chaves-Almagro, Carline; Bai, Yushi et al. (2017) Protamine is an antagonist of apelin receptor, and its activity is reversed by heparin. FASEB J 31:2507-2519
Jean-Charles, P-Y; Snyder, J C; Shenoy, S K (2016) Chapter One - Ubiquitination and Deubiquitination of G Protein-Coupled Receptors. Prog Mol Biol Transl Sci 141:1-55
Meza-AviƱa, Maria Elena; Lingerfelt, Mary A; Console-Bram, Linda M et al. (2016) Design, synthesis, and analysis of antagonists of GPR55: Piperidine-substituted 1,3,4-oxadiazol-2-ones. Bioorg Med Chem Lett 26:1827-1830
Barak, Larry S; Bai, Yushi; Peterson, Sean et al. (2016) ML314: A Biased Neurotensin Receptor Ligand for Methamphetamine Abuse. ACS Chem Biol 11:1880-90
Snyder, Joshua C; Pack, Thomas F; Rochelle, Lauren K et al. (2015) A rapid and affordable screening platform for membrane protein trafficking. BMC Biol 13:107

Showing the most recent 10 out of 22 publications